

Sec/Share /031/FY 2021-22

Dated: 03.09.2022

**The Secretary**  
**BSE Limited**  
New Trading Wing,  
Rotunda Building,  
PJ Tower, Dalal Street,  
Mumbai- 400001  
Security code: 532932

**The Manager**  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block "G"  
5<sup>th</sup> floor, Bandra Kurla Complex,  
Bandra East,  
Mumbai- 400051  
Symbol: MANAKSIA

Sir,

**Sub: Newspaper publication- Information on E-Voting and other related information relating to ensuing 38<sup>th</sup> Annual General Meeting of the Company.**

With reference to the captioned subject, we would like to inform you that the Company has published advertisement in all editions of Business Standard (English) and Ekdin (Bengali) newspapers on 3<sup>rd</sup> September, 2022 in compliance with Ministry of Corporate Affairs Circular dated April 8, 2020, April 13, 2020, May 5, 2020, January 13, 2021, December 14, 2021 and May 5, 2022, intimating that the 38<sup>th</sup> Annual General Meeting of the Company will be held on Tuesday, 27<sup>th</sup> September, 2022 at 12.30 pm IST through Video Conferencing / Other Audio Visual Means and information on E-voting and other related information relating to 38<sup>th</sup> Annual General Meeting.

Further, in terms of Regulation 30 and other applicable regulations, if any, of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of each of the aforesaid newspaper clippings of the advertisement published on 3<sup>rd</sup> September, 2022.

Thanking you  
Yours faithfully,

For MANAKSIA LIMITED



Pradip Kumar Kandar  
Company Secretary



Encl: as above

# A health shot for indigenous vaccines

The locally developed Cerovac can play a critical role in the efficacy of the National Immunisation Mission

SOHINI DAS  
Mumbai, 2 September

The first doses of smallpox vaccine lymph arrived in India in May 1902. A three-year-old child from Bombay (now Mumbai) — Anna Dusthall became the first person in India to receive the smallpox vaccine on May 14, 1902.

For 150 years, India was using vaccines imported from Britain until Dr Waldemar Hafslund developed cholera and plague vaccines through clinical trials in India in the late 19th century.

India's National Immunisation Mission has come a long way since. But it still needs a supply of indigenously developed vaccines to run the world's largest universal immunisation programme.

For example, vaccines for human papillomavirus (HPV) that is known to cause cervical cancer and rotavirus that causes potentially lethal diarrhoea in children could be included in the NIM only after local players developed them at affordable rates.

This July, after over a decade's hard work, the first indigenously developed HPV vaccine Cerovac received approval from the country's drug regulator. The vaccine has a two-dose and a three-dose regimen depending on the age of the person.

Co-developed by the Department of Biotechnology and Pune-based vaccine maker Serum Institute of India (SII), the vaccine is expected to cost between ₹200

and ₹400 per dose as against the currently available vaccines Gardasil (Merck) and Cervarix (GlaxoSmithKline) that cost ₹2,000-3,500 per dose.

Affordability is going to be the driver. "Although there has always been a considerable demand for multinational vaccines, the cost of these has always been a concern. Now with an affordable HPV vaccine available for cervical cancer, a much larger population will have access to the vaccine, which might reduce the incidence of cervical cancer," Sonal Kumta, senior consultant obstetrician & gynaecologist, Fortis Hospital, Mulund, Mumbai.

The government policy think tank, National Technical Advisory Group on Immunisation (NTAGI), has wanted to include the HPV vaccine in the list of vaccines that are part of the NIM for a while. India was, however, waiting for an indigenously developed affordable vaccine to be able to do so.

The concerns stem from the fact that cervical cancer ranks as the second most frequent cancer among women in India. About 5 per cent of women in the general population are estimated to have

been infected with HPV-16/18 infection at a given time, and 83.2 per cent of invasive cervical cancers are attributed to HPV-16 or its HPV infection is now well-established cause of cervical cancer and HPV types 16 and 18 are the most frequent and responsible for about 70 per cent of all cervical cancer cases worldwide.

## IMMUNISATION JOURNEY

1978: Expanded Programme of Immunisation (EPI)  
■ Limited reach — mostly urban

1985: Universal Immunisation Programme (UIP)  
■ Indigenous vaccine production capacity enhanced  
■ Cold chain established

1986: Technology Mission On Immunisation

India has a population of 48.35 million women aged 15 years and older who are at risk of developing cervical cancer. Current estimates indicate that every year 123,907 women are diagnosed with cervical cancer and 77,348 die from it. Cervical cancer ranks as the second most frequent cancer among women in India and the second most frequent cancer among women between the ages of 15 and 44.

Doctors say that having an India-made low-cost vaccine

will help spread the coverage. "As gynaecologists, we get this demand for the vaccine, especially in females, who had cervical cancer history in their families. The low socio-economic strata are still not very much aware of the vaccine. If this vaccine comes and it is launched, which is expected in December, at a rate of ₹200-400, it's definitely going to be a boon and the number of people who will go in for vaccination is also going to increase," said Ananta Singh, director and head of department, obstetrics and gynaecology, Fortis Hospital Noida.

The Cerovac project was conceptualised in September 2011 and there have been 30 meetings of the scientific bodies, and the industry partners since then to discuss the scientific development of this vaccine.

Bharat Biotech developed Cerovac's story is similar — the vaccine originated from a new strain of rotavirus 116E, isolated from an Indian asymptomatic infant at the All India Institute of

Medical Sciences in New Delhi in 1986. In India alone, around 13,000 infants die every year due to rotavirus diarrhoea (one infant death a month) and 450,000 infants succumb to the disease globally. Rotovac is a three-dose orally administered vaccine given to infants.

Almost two decades of work went into developing the Rotovac 5D. The Government of India's Department of Biotechnology (DBT), along with several public sector scientific institutions, Stanford University School of Medicine, the US National Institutes of Health (NIH), the US Centers for Disease Control and Prevention (CDC), and the non-profit organisation PATH have all worked as a team to develop Rotovac 5D.

Bharat Biotech's Rotovac became a part of the NIM around 2016. The company supplied the vaccine at ₹70 per dose to the government. In 2019, it upgraded the vaccine further to Rotovac 5D, which entailed a smaller dose of 0.5 ml as against its competitors 2.5-ml per dose.

The country had then said that trials had revealed that many infants could not swallow a 2.5 ml dose and would spit it out. This oral vaccine was being supplied to the government at around ₹100-110 per dose. The NIM around 2016. The company supplied the vaccine at ₹70 per dose to the government. In 2019, it upgraded the vaccine further to Rotovac 5D, which entailed a smaller dose of 0.5 ml as against its competitors 2.5-ml per dose.

declares 2012 as 'Year of Intensification of Routine Immunisation'

2013: India, along with other South-East Asia Region, declares commitment towards measles elimination and rubella (congenital rubella syndrome (CRS) control by 2020

2014: India is certified 'polio free country'

2015: National Rural Health Mission (NRHM)

2016: Government of India

healthcare comes at a premium, such indigenous initiatives could go a long way towards improving health outcomes for the average Indian.

In a country where good health comes at a premium, such indigenous initiatives could go a long way towards improving health outcomes for the average Indian.

# Monkeypox jab might not be as potent: Research

JASON GALE  
2 September

The monkeypox vaccine that's become the main method doctors are using to try to stop the global scourge may be less potent than hoped, new research shows.

The recommended series of shots with Bavarian Nordic's JYNneos vaccine yielded markedly low levels of monkeypox antibodies with poor neutralising capacity, researchers at the Erasmus University Medical Center in Rotterdam, Netherlands, said. Those immunised hadn't been previously infected or vaccinated against smallpox, which is believed to provide some protection against monkeypox.

Neutralising antibodies have become part of the common lexicon during the Covid era thanks to their ability to bind to the coronavirus and stop it from entering healthy cells. Although these proteins are almost certainly needed to prevent a monkeypox infection and the rash it causes, scientists don't know yet what levels are required to confer protection.


"The level of optimism for the vaccine far exceeds the data currently available," said Helen Petousis-Harris, a vaccinologist at the University of Auckland, who was not involved in the research.

The finding of lower-than-expected levels of neutralising antibodies raises questions about how well vaccinated individuals are protected, wrote Erasmus scientists Mariska Koopmans, Rory de Vries and their co-authors in the paper that was released Thursday ahead of peer review.

Authorities in more than 70 countries are seeking supplies of the Danish company's vaccine, also sold as Imvamune in Canada and Imvanex in Europe, to thwart the global spread of monkeypox. It has infected more than 50,000 people since a flare-up of the disease was reported in the UK in early May.

BLOMBERG

# 3D-printed jewellery, homes, implants: An industry takes shape



DEBANGHNA SANYAL  
New Delhi, 2 September

If you have seen the hit HBO series *Westworld*, you would remember the haunting visuals of a robotic 3D printer's arm building fully grown human bodies, sinewy by delicate string. While fully formed 3D printed androids may remain a thing of sci-fi fantasy for now, 18-year-old Payal Solanki can testify that 3D printing is indeed changing lives in Indian medicine.

Solanki recently became the first Indian to receive a 3D-printed spine brace from the Pt Deendayal Upadhyaya National Institute for Persons with Physical Disabilities, Delhi. "The process was quite hassle-free, and not time consuming at all," she says. The institute did not charge her.

Pandian, the doctor who conducted the procedure, confirms that "as compared to the traditional process, which involves manual measurements and casting, 3D printing braces and other medical prosthetics are much more accurate and efficient."

Prosthetics aren't the only area of healthcare where 3D printing is making waves. At the IIT Hyderabad-led Prasad Life Institute, researchers successfully printed and transplanted an artificial cornea into a rabbit's eye, making 3D printed implants a possibility.

Nor is healthcare the only sector. With Prime Minister Narendra Modi's "Panch Pran" declaration on Independence Day, 3D printing is set to receive a massive boost from the Ministry of Electronics and Information Technology (MeitY) in its application across sectors such as automotive, space research and imitation jewellery.

In a recent publication titled "National Strategy for Additive Manufacturing," MeitY empha-

## 3D NUMBERS

The Asia-Pacific region commands 28 per cent share of the global 3D printing market. China makes up 50 per cent of Asian markets, and the global market. India's share is a meagre 5 per cent within Asia and 1.4 per cent globally.

sised the government's push for incorporating 3D printing as a core strategy towards achieving its "Make in India" promise. The publication admitted, however, that compared to global markets such as the United States, Japan, and China, "the adoption of 3D printing hasn't seen much traction in India."

3D printing uses what's often called additive manufacturing (AM); compressing layers of raw materials into each other in the shape of specific objects. Somewhat counterintuitively, given its name, it is an additive manufacturing in fact uses very less raw material, generates less waste, and saves time, manpower and money.

So far, AM is primarily used for prototyping, designing, and tooling across sectors like automotive, consumer durables, engineering, medical devices, and defence. (Tooling refers to producing small tools like jigs, gauges, moulds, dies, cutting equipment and patterns.) However, market leaders like GE Additive are pushing the envelope in this direction.

At Nanda, chief technology officer, GE South Asia, and CEO, GE's India Technology Centre, mentions the company's "Pacer Edge" Pathfinder programme with the US Air

Force (USAF). Now in its third stage, the 3D programme prints obsolete and out-of-production metal spare parts for replacement and repair purposes in US warfighters.

Closer home, Noida-headquartered ARK Infotech is researching Nano 3D printing and 3D printed electronics to print functional plastic parts to be fitted with circuits. ARK aims to develop these printers for full-scale productions and not just prototypes.

IIT Madras-based start-up Tvasta, meanwhile, grabbed eyeballs when its 3D-printed eye — India's first — was inaugurated in April 2021. And earlier this year, Chennai-based space-tech start-up Agnikul Cosmos opened the country's first factory dedicated to building 3D-printed rocket engines.

Besides these success stories, AM is also fuelling a minor revolution in the jewellery industry. Imaginarium, one of India's fastest-growing 3D printing and rapid prototyping companies, has partnered with giants like PC Jewellers and Titan Industries, and is 3D printing pieces of jewellery from gold and other precious metals.

AM is leading the way clearly. It has been made, but there are hurdles yet. Procurement costs of 3D printing machines and set-ups are high. And these are rooted in the exorbitant excise duties that companies must pay when importing AM equipment for R&D purposes, says Nimesh Soni, national manager of digital manufacturing, ARK Infotech.

Industrial printers for additive manufacturing cost anywhere between ₹5 lakh and ₹5 crore, metal 3D printers range from ₹5 crore to ₹15 crore.

**REFEX INDUSTRIES LIMITED**  
CORPORATE OFFICE: 401/01, Prithvi, 222, 223 & 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000.

**CORRIGENDUM TO THE NOTICE OF 20TH ANNUAL GENERAL MEETING (e-AGM) PUBLISHED ON SEPTEMBER 02, 2022 REGARDING e-AGM**  
NOTICE is hereby given that the date of dispatch of the Notice of the 20th e-AGM through e-mails has been completed on Thursday, September 01, 2022 (which was inadvertently reported as on Wednesday, August 30, 2022). Rest of the contents of the Notice remains the same.

**Manaksia Limited**  
Regd. Office: Turner Morrison Building, 6 Lyons Range, Mazgaon, Fort, North-West Corner, Kolkata - 700 011  
Phone No.: +91-33-22310055; Fax No.: +91-33-22303336  
Email: investor.relations@manaksia.com; Website: www.manaksia.com  
Corporate Identity Number: L74950WB1984PLC38338

**NOTICE OF THE 38TH ANNUAL GENERAL MEETING**  
Notice is hereby given that 38th (Thirty Eighth) Annual General Meeting ("AGM") of the members of Manaksia Limited ("the Company") will be held through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM") on Tuesday, 27th September, 2022 at 12:30 P.M. (IST), in compliance with applicable provisions of the Companies Act, 2013 and Rules made thereunder and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations, 2015) read with Circular dated 8th April 2020, 13th April 2020, 5th May 2020, 13th January 2021, 14th December, 2021 and 5th May, 2022 issued by the Ministry of Corporate Affairs and SEBI Circular dated May 13, 2022 and all other relevant circulars issued from time to time, it is hereby notified that the "Relevant circulars" to transact the businesses set out in the notice calling AGM, without the physical presence of the Members at a common venue.

Members are hereby informed that in compliance with the relevant circulars, the Notice of the AGM and the Annual Report for the FY 2021-22 have been sent electronically on 2nd September, 2022 to all the members of the Company whose email addresses are registered with the Company/Depository Participants. The Notice and the Annual Report for the FY 2021-22 are available on the website of the Company at (www.manaksia.com) and on the website of the stock exchanges where equity shares of the Company are listed viz., (www.bseindia.com) and (www.nseindia.com). Physical copy of the aforesaid documents, are not being sent to the shareholders as the requirement has been relaxed vide relevant circulars. The Notice is also available on the e-voting website of NSDL (Agency engaged for providing e-Voting facility) viz., (www.evoting.nsdl.com).

Members, who have not registered their email address (including Members holding shares in physical form) with the Company/Depository Participant(s), are requested to update the same in the manner specified in para 4 of the Notice. Members are also requested to refer to newspaper publication dated 17th August, 2022 issued by the Company in Business Standard (English) and Ekin (Bengali) for other details pertaining to the Notice. The said advertisement is also available on the website of the Company and of the Stock Exchanges where the equity shares of the Company are listed. The Resolutions covered in the Notice of the 38th AGM will be transacted through remote e-voting facility to cast vote from a place other than the venue of the AGM in terms of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014. Secretarial Standards on General Meetings and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. National Securities Depository Limited (NSDL) (Agency engaged for providing e-Voting facility) will also be available at the AGM and members who have not cast their votes by remote e-voting and are otherwise not debarred from doing so, will be able to vote at the AGM.

Members, whose names are recorded in the Register of Members of the Company or in the Register of Beneficial Owners maintained by the Depositories as on the cut-off date i.e., Tuesday, the 20th September, 2022 will be entitled to cast their votes either by remote e-voting or through e-voting at the AGM. A person who is not a Member as on the cut-off date should accordingly treat the Notice of the AGM for information purposes only. Persons becoming Members of the Company after dispatch of the Notice of the AGM but on or before the cut-off date may write to NSDL at evoting@nsdl.co.in or kolkata@nsdl.co.in for an e-mail ID and password for remote e-voting. Members already registered with NSDL for remote e-voting can however use their existing user ID and password for this purpose.

Pursuant to the provisions of Section 91 of the Companies Act, 2013 and Regulation 42 of the Listing Regulations, 2015, the Register of Members & Share Transfer Books of the Company will remain closed from Wednesday, the 21st September, 2022 to Tuesday, the 27th September, 2022 (both days inclusive) for the purpose of 38th AGM of the Company.

The period for remote e-voting will start at 09:00 A.M. (IST) on Friday, the 23rd September, 2022 and will end at 05:00 P.M. (IST) on Monday, the 26th September, 2022, thereafter the remote e-voting will be blocked by NSDL. Further, once the vote on a resolution is cast by the member, the same shall not be allowed to be changed subsequently. Members who have cast their votes by remote e-voting may attend the meeting but will not be entitled to cast their votes at the meeting once again.

Members are requested to carefully read all the Notes set out in the Notice of the AGM and in particular, instructions for joining the AGM, manner of casting vote through remote e-voting/e-voting during the AGM.

In case of any query / grievance with respect to Remote e-Voting, members may refer to the Frequently Asked Questions (FAQs) for Shareholders and Remote e-Voting User Manual for Shareholders available under the Downloads section of NSDL's e-Voting website or contact Mr. Arvind Vishal, Senior Manager / Ms. Pallavi Mhatre, Manager, NSDL, Trade World, "A" Wing, 4th Floor, Kamala Mills Compound, Lower Parel, Mumbai-400 013 at toll free no. 1800-1020-990 / 1800-224-430 or e-mail ID: evoting@nsdl.co.in.

Helpdesk for Individual Shareholders holding securities in Demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

Vinod Kothari & Company, Practising Company, Practising Companies, Kolkata has been appointed as the Scrutinizer to scrutinize the remote e-voting and voting during the AGM in a fair and transparent manner.

The Results of voting will be declared within two working days from the conclusion of the 38th AGM. The declared Results along with the Scrutinizer Report will be available forthwith on the Company's corporate website www.manaksia.com and on NSDL's e-voting website. Such Results will also be forwarded by the Company to the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE).

By Order of the Board of Directors of FOR GOLDCREST CORPORATION LIMITED  
Sd/-  
Date: September 2, 2022  
Place: Mumbai  
Company Secretary & Compliance Officer

**Manaksia Limited**  
Regd. Office: Turner Morrison Building, 6 Lyons Range, Mazgaon, Fort, North-West Corner, Kolkata - 700 011  
Phone No.: +91-33-22310055; Fax No.: +91-33-22303336  
Email: investor.relations@manaksia.com; Website: www.manaksia.com  
Corporate Identity Number: L74950WB1984PLC38338

**NOTICE OF THE 38TH ANNUAL GENERAL MEETING**  
Notice is hereby given that 38th (Thirty Eighth) Annual General Meeting ("AGM") of the members of Manaksia Limited ("the Company") will be held through Video Conferencing ("VC")/Other Audio Visual Means ("OAVM") on Tuesday, 27th September, 2022 at 12:30 P.M. (IST), in compliance with applicable provisions of the Companies Act, 2013 and Rules made thereunder and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations, 2015) read with Circular dated 8th April 2020, 13th April 2020, 5th May 2020, 13th January 2021, 14th December, 2021 and 5th May, 2022 issued by the Ministry of Corporate Affairs and SEBI Circular dated May 13, 2022 and all other relevant circulars issued from time to time, it is hereby notified that the "Relevant circulars" to transact the businesses set out in the notice calling AGM, without the physical presence of the Members at a common venue.

Members are hereby informed that in compliance with the relevant circulars, the Notice of the AGM and the Annual Report for the FY 2021-22 have been sent electronically on 2nd September, 2022 to all the members of the Company whose email addresses are registered with the Company/Depository Participants. The Notice and the Annual Report for the FY 2021-22 are available on the website of the Company at (www.manaksia.com) and on the website of the stock exchanges where equity shares of the Company are listed viz., (www.bseindia.com) and (www.nseindia.com). Physical copy of the aforesaid documents, are not being sent to the shareholders as the requirement has been relaxed vide relevant circulars. The Notice is also available on the e-voting website of NSDL (Agency engaged for providing e-Voting facility) viz., (www.evoting.nsdl.com).

Members, who have not registered

